Generated August 8, 2026.
Overview
CHPS and SMH are both semiconductor-focused equity ETFs, but they differ sharply in scale, track record, and volatility profile. SMH is the established $71.5B VanEck flagship that tracks the MVIS US Listed Semiconductor 25 Index and dates to 2011; CHPS is a much newer $106M DWS product from July 2023 with higher beta and a lower expense ratio. Both aim to capture semiconductor sector upside, but through different selection strategies and investor bases.
How they differ
SMH tracks a named 25-stock index, while CHPS uses a "select equity" approach—a less transparent methodology that DWS doesn't detail in the provided data. SMH has been in operation for over a decade and manages $71.5B in assets; CHPS arrived in mid-2023 with $106M. The bigger structural gap: CHPS carries a beta of 2.46 versus SMH's 1.98, meaning CHPS amplifies semiconductor sector moves by roughly 24% more than SMH does. On cost, CHPS charges 0.15% versus SMH's 0.35%, though that advantage matters less when AUM and liquidity differ by three orders of magnitude. Distribution yields are both minimal—0.19% for SMH and 0.32% for CHPS—making income secondary in both cases.
Who each is best for
CHPS: Fits investors seeking concentrated semiconductor exposure with higher sensitivity to sector swings and who are comfortable with a newer fund that hasn't weathered a full market cycle or economic downturn.
SMH: Designed for long-term semiconductor allocators who value a well-established track record, deep liquidity, an explicit index methodology, and modest cost for the strategy—even if the expense ratio is higher than newer competitors.
Key risks to know
- Selection opacity on CHPS. DWS's "select equity" approach is not defined in the fund prospectus summary provided, leaving investors unable to verify what drives stock inclusion or how it differs from SMH's transparent index rules.
- Beta asymmetry. CHPS's 2.46 beta means it will magnify both upside and downside moves in semiconductors. In a sector downturn, CHPS could decline 46% more than a 1.0-beta baseline, while SMH at 1.98 would fall roughly 40% more. This amplification can erode capital during extended weakness.
- Liquidity and tracking risk. CHPS's $106M AUM versus SMH's $71.5B creates meaningful difference in spreads, creation/redemption efficiency, and ability to rebalance without market impact. Newer funds also face closure risk if assets don't grow.
- Concentration in a cyclical subsector. Both ETFs are pure semiconductor plays with no diversification outside the industry. Semiconductor stocks are cyclical and sensitive to chip cycle downturns, capacity announcements, and geopolitical supply-chain disruption.
Bottom line
SMH offers a proven index framework and institutional scale; CHPS promises lower fees and higher beta sensitivity, but with a newer track record and an opaque selection process. If you prioritize transparency, liquidity, and a long operating history, SMH's structural advantages likely carry weight. If you're confident in a strong semiconductor cycle and want to minimize costs while accepting higher volatility and less established liquidity, CHPS's beta and expense ratio may align with your risk tolerance. Past performance does not predict future results.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.